MSR1 and breast cancer: Several studies demonstrated that CD204+TAMs promote tumor development and correlate with worse prognoses in prostate cancer, lung cancer, colorectal cancer, cervical cancer, breast cancers and oral squamous cell carcinoma patients (24, 26, 27, 74–76).